Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fresenius Medical Care AG & Co. KGaA

Investor Presentation • May 11, 2010

165_ip_2010-05-11_e6ba8e39-d45b-40a2-9eb1-e3abc846af8a.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

Fresenius Medical Care

The World's Leading Renal Therapy Company

Annual General Meeting

Frankfurt am Main, May 11, 2010

Accomplishments and Business Update

Global Leadership Position

Growth Strategy and Summary

Accomplishments for 2009

We achieved record results and delivered our Target

Fiscal Year 2009Another Record Year

i
(
)
O
I
E
B
I
T
t
p
e
r
a
n
g
n
c
o
m
e		 1
5
6
7
,		 5
+
------------------------------------------------------------------------------------------------------- ----------------------- -------- --
N
I
t
e
n
c
o
m
e		 8
9
1		 9
+
------------------------------------------- ------------- --------

2009 Strong Revenue Growth in all Regions

Total revenue increased 6% to \$11,247 m

Impressive Growth Continued

RevenueNet Income

(in \$ million) (in \$ million)

We Created Jobs Worldwide

Strengthened Balance Sheet

2009 Annual Dividend Proposal

Share Price Development Last 12 Months

Page 10

Strong First Quarter 2010

Clearly on track for our 2010 guidance and another record year

Q
1
2
0
1
0		 %
h
t
g
r
o
w
2
8
8
2
,		 1
0
%
+
1
3
t
t
t
+
a
c
o
n
s
a
n
c
r
r
e
n
c
u
y
4
2
3		 7
+
2
1
1		 7
+

Accomplishments and Business Update

Global Leadership Position

Growth Strategy and Summary

Global Presence Products & Services

Dialysis Services Worldwide – Number of Patients Treated 2009*

* Based on company statements and estimates

* * 13,606 patients including managed clinics

Market Position Globally

1,895,000 Dialysis Patients in 2009

Dialysis patients treated in 2009 by company

Market Positionby Major Product Groups

R
k
1
a
n		 R
k
2
a
n		 R
k
3
a
n
i
D
l
a
e
r
s
y
z		 F
M
E		 G
b
a
m
r
o		 N
i
p
r
o
D
i
l
i
h
i
a
y
s
s
m
a
c
n
e
s		 F
M
E		 G
b
a
m
r
o		 N
i
k
k
i
s
o
H
d
i
l
i
t
t
e
m
o
a
y
s
s
c
o
n
c
e
n
r
a
e
s		 F
M
E		 F
u
s
o		 G
b
a
m
r
o
B
l
d
l
i
o
o
n
e
s		 F
M
E		 G
b
a
m
r
o		 i
K
a
w
a
s
u
m
P
i
l
d
i
l
i
d
t
t
e
r
o
n
e
a
a
s
s
p
r
o
c
s
y
u		 B
t
a
e
r
x		 F
M
E		 P
i
s
a

Produced more than ~85,000,000 Dialyzers in 2009

Accomplishments and Business Update

Global Leadership Position

Growth Strategy and Summary

Global View of Dialysis Patients

Global prevalence increased by 80% over the last 10 years

Page 18

Dedication to Quality

Services – Reduction in Mortality

North America 2005 – 2009: 21%

Europe 2005 – 2009: 13%

Products – Bloodlines

Reynosa, Mexico 2002 – 2010: 85% Improvement in Quality

Achieved less than 3 complaints per million while producing 73 million bloodlines per year

Development of Dialysis Patient Numbers

  • Renal failure persists worldwide
  • Dialysis is the primary treatment modality on a global scale
  • The number of global dialysis patients is expected to double by 2020

Continued Growth Opportunities

F
i
s		 l
Y
O
l
k
2
0
1
0
t
c
a
e
a
r
o
o
u
–
\$
i
i
l
l
i
n
m
o
n
s
R
e
e
n
e
v
u		 1
2
0
0
0
>
,
N
i
t
e
n
c
o
m
e		 \$
9
5
0
9
8
0
-
C
i
i
l
d
t
t
a
p
a
e
p
e
n
r
e
s
x
u		 \$
5
5
0
6
8
0
-
A
i
i
i
t
c
q
s
o
n
s
u		 \$
4
0
0
<
=

Strong growth expected for 2010

Our global presence, growth and profitability is market leading

Vertical integration was and will be the best business model

There are many opportunities but also challenges

We will confidently continue to pursue our growth strategy, and we will remain vigilant with respect to:

Thank You for your interest in Fresenius Medical Care !

Fresenius Medical Care

The World's Leading Renal Therapy Company

Annual General Meeting

Frankfurt am Main, May 11, 2010

Contacts

Fresenius Medical Care AG & Co. KGaAInvestor RelationsElse Kröner Str. 161352 Bad Homburg v.d.H.

Ordinary shares WKN 578 580ISIN DE0005785802SEDOL1 5129074 DE

Oliver Maier

Head of Investor Relations & Corporate Communications

Tel.: +49-(0)6172-609-2601 Fax.: +49-(0)6172-609-2301 Email: [email protected]

Gerrit Jost

Tel.: +49-(0)6172-609-5216 Fax.: +49-(0)6172-609-2301 Email: [email protected]

Terry L. Morris

Tel.: +1-800-948-2538Fax.: +1-615-345-5605Email: [email protected]

More from Fresenius Medical Care AG & Co. KGaA

Regulatory Filings 2026
Jan 16
Share Issue/Capital Change 2026
Jan 12
Transaction in Own Shares 2026
Jan 9
Share Issue/Capital Change 2025
Dec 29
AGM Information 2025
Dec 22
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 15
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 12
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 8
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 3
Transaction in Own Shares 2025
Dec 1
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.